{"ticker": {"uuid": "59fa6bba-f149-4e39-a67b-91bdefe19e5f", "symbol": "XLO", "name": "Xilio Development Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Xilio Therapeutics, Inc. announced the grant of non-qualified stock options to purchase 107,060 shares of its common stock to three new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan, with an exercise price of $9.22 per share, matching ", "url": "https://finance.yahoo.com/healthcare/articles/xilio-therapeutics-announces-inducement-grants-203000264.html", "source_name": "Market source", "published_at": "2026-07-09T12:42:25", "published_display": "09 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xilio Therapeutics, Inc. \u2013 NASDAQ:XLO", "summary": "This article focuses on the enterprise value to EBIT forward for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content primarily consists of navigational and bra", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:11:18", "published_display": "07 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio lures three new employees with 107,060 stock options", "summary": "Xilio Therapeutics (Nasdaq: XLO) has granted non-qualified stock options for 107,060 shares to three new employees, effective July 1, 2026. These options, with an exercise price of $9.22 per share and a ten-year term, serve as an inducement under Nasdaq Listing Rule 5635(c)(4). T", "url": "https://www.stocktitan.net/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-w0d8bd87n4rj.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:09:27", "published_display": "06 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his over two decades of legal and executive experience in the biopharmaceutical industry. Harshbarger previously served as chief legal officer at Astria Therapeutics and held leadership ro", "url": "https://za.investing.com/news/stock-market-news/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-93CH-4347544", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T08:09:48", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xilio Therapeutics, Inc. \u2013 NASDAQ:XLO", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company over a defined period. The content primarily lists nav", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:19", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index", "summary": "Xilio Therapeutics, Inc. (NasdaqCM:XLO) has been added to the Russell Microcap Value Benchmark Index, as announced on June 29, 2026. This move highlights the company's position within the microcap market and its valuation metrics. Xilio Therapeutics operates as a clinical-stage b", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-nasdaqcm-xlo-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:11:24", "published_display": "29 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. \u2013 BOATS:XLO", "summary": "This article provides financial information for Xilio Therapeutics, Inc. (XLO), specifically its enterprise value to EBITDA forward metric. The content highlights a specific financial indicator for the company, accessible through the Blue Ocean Alternative Trade System (BOATS) vi", "url": "https://www.tradingview.com/symbols/BOATS-XLO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:11:24", "published_display": "29 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer", "summary": "Xilio Therapeutics, Inc. has announced the appointment of Ben Harshbarger as its new Chief Legal Officer. Harshbarger brings over two decades of legal and executive leadership experience in the biopharmaceutical industry, having previously served as Chief Legal Officer at Astria ", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-announces-appointment-of-ben-harshbarger-as-chief-legal-officer-ce7f5fded08af324", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:11:24", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his extensive legal and strategic experience in the biotechnology sector. Harshbarger's role will be crucial in advancing Xilio's pipeline of immuno-oncology therapies, including the bispe", "url": "https://www.quiverquant.com/news/Xilio+Therapeutics+Appoints+Ben+Harshbarger+as+Chief+Legal+Officer", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T11:41:00", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, bringing over 20 years of biopharmaceutical legal and executive experience to the company. Harshbarger previously served at Astria Therapeutics, Novelion Therapeutics, Aegerion, Cubist, ViaCell, and ", "url": "https://www.stocktitan.net/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-jsgkw9sa1yho.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:11:24", "published_display": "29 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xilio Therapeutics, Inc. \u2013 BOATS:XLO", "summary": "The article focuses on the enterprise value to revenue forward metric for Xilio Therapeutics, Inc. (XLO). It appears to be a financial data presentation or analysis page from TradingView, specifically looking at Xilio Therapeutics' financials within the pharmaceutical sector. The", "url": "https://www.tradingview.com/symbols/BOATS-XLO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:41:09", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index", "summary": "Xilio Therapeutics, Inc. (NasdaqCM: XLO) has been added to the Russell Microcap Index. The clinical-stage biotechnology company focuses on developing masked immuno-oncology therapies to treat cancer with reduced systemic side effects. Xilio Therapeutics also reported its first-qu", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-nasdaqcm-xlo-added-to-russell-microcap-index-ce7f5fdedd88f520", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T01:50:00", "published_display": "29 Jun 2026 01:50", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XLO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Xilio Therapeutics, Inc. (XLO) stock, based on analyst opinions. It covers current stock performance, historical highs and lows, volatility metrics, market capitalization, and financial data including earnings, revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:26", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO)", "summary": "This article provides an overview of Xilio Therapeutics Inc. (NASDAQ: XLO), including its current stock price, historical performance, analyst forecasts, and financial data. It covers earnings per share, revenue, market capitalization, and volatility, along with information on fu", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:56", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Edges Higher in Low-Volume Trading, Testing Key Resistance - OBV Trend Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOXZFZi1ONWpWQl9EREwySVdPQjdpSWR5djRMclFPVENndzR2SG9XX0FGRHFxOFphZnNXQW9pZ2VRV1dCZzQ2clpENTRBLU9YLXY5Y29UaHdTRG5xN3JDS3MwZ19kdjdtV2hmYzVIc3haM2paN25wNFNuMU5PcjRjdU94WkY5TmJKbnhNRkFTUUh3aUZGUmk2b19MYnYycmduTFlQaFJtbW9ReDBFdGxXZmxWLVU4aU5iWEJN?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividends and stock splits for Xilio Therapeutics Inc (XLO). It indicates that the company has not distributed any dividends in the past five years. However, it notes a 14-to-1 merger-related stock split effective March 12, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xlo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xilio Therapeutics Inc (XLO), highlighting its perfect earnings forecast score of 10.00 and a 'Strong Buy' analyst rating from one analyst. It details the average price target of $2.00, along with expected revenue and EPS for upcomin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xlo/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T01:40:39", "published_display": "17 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes", "summary": "Xilio Therapeutics has modified its board structure following its annual meeting by rebalancing its classified board and reappointing Daniel Curran as a Class III director. Shareholders also elected four Class II directors, ratified Ernst & Young LLP as the auditor, and approved ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XLO-Q/pressreleases/2458209/xilio-therapeutics-adjusts-board-structure-following-shareholder-votes/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T02:39:53", "published_display": "14 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio (XLO) director receives grant of 5,000 stock options at $7.99", "summary": "Xilio Therapeutics director Shannon James Samuel was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company\u2019s next annual stockholder meeting, contingent on his continued service. Following", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-cca81b1d18ac.html", "source_name": "Stock Titan", "published_at": "2026-06-13T13:09:59", "published_display": "13 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99", "summary": "Xilio Therapeutics director Daniel J. Curran was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company's next annual meeting, contingent on his continued service. This transaction is a com", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-9a32f35e3b52.html", "source_name": "Stock Titan", "published_at": "2026-06-13T12:10:28", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daniel Curran reappointed to Class III director at Xilio", "summary": "Xilio Therapeutics has reappointed Daniel Curran as a Class III director after he resigned as a Class II director to rebalance the board. This change, effective June 10, 2026, aims to achieve an equal balance of director membership across the three classes of the Board. The infor", "url": "https://www.tradingview.com/news/tradingview:69c8358eb5b5c:0-daniel-curran-reappointed-to-class-iii-director-at-xilio/", "source_name": "TradingView", "published_at": "2026-06-12T20:39:41", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO)", "summary": "Xilio Therapeutics (NASDAQ: XLO) reported governance and compensation updates from its 2026 annual stockholder meeting. The company rebalanced its staggered board, moving Daniel Curran, M.D. from a Class II to a Class III director position without changing his compensation. Stock", "url": "https://www.stocktitan.net/sec-filings/XLO/8-k-xilio-therapeutics-inc-reports-material-event-82f08ec0c610.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:42", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options", "summary": "Xilio Therapeutics director Xu Yuan was granted 5,000 stock options as equity compensation, with an exercise price of $7.99 per share and an expiration date of June 10, 2036. The options, granted on June 11, 2026, will fully vest on the earlier of June 11, 2027, or the company's ", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-434d6ace3642.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:41", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99", "summary": "Xilio Therapeutics director Aoife Brennan was granted options for 5,000 shares of common stock at an exercise price of $7.99 per share. The options expire on June 10, 2036, and will vest 100% on the earlier of June 11, 2027, or the next annual stockholder meeting, contingent on h", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-9a2083d16127.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:41", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Shows Resilience with 1.91% Gain, Approaching Key Resistance - Dark Pool Prints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPSGRPazFBRVppVUZ5Z3ltdDk4VlBwWGxwNWxiRFN3T21YN3hyelZBZG9lcklndTlYZUFfWGJtQnhvTFM0VzBUMm90LV85ZmRBSF91WVJidVN0ODlsdGhVeFpFZWY1cU9uX2dPWE1ZWmUxM0ppNlE2aTlhX0JJc21RZlNReVFSWmc1YkhESDI5VnVuT2dDR0xaNUM1bU12ajhteWRTanFwUDJWUE1pNl9sSmZjV0Q1enVIenMtc1dfcHJqQnM?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSThhdGU0UG1nSV9zYVZ5ZFlwdnR3UFZjSmVfVm44TFRrZHhPWndRdF9kUmpTbUVOVXdHLVFrb3l4cGZXSFB3TG9xeWpEQWhtUDNRalo2Z3phYkYwbjBxMDg0dlhSUUxhLVVvOTZYTDVuYTlONmRldWFYelFQMkR5R0NiU3gtajd2RWxoc2tzWmpWVWdqU1dtUjcwLWVVMXNEMEp2LUJ3?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxNdVduVnhqV2JRbVpJX0tzbGNlb2ROM2JUc01FWllsMW5TT3I2S0lvemJ2SWNkaGVLV1hlTHlESWFQRE9vckZ1UUFYREo0TnU2NUtaVE04cWs2eVhkWFY2bDdwcnR1MHJtME1xakh6T3hMUlhKVXlHbEJNeGNOcGlhNFBzTVBYSWU4OFM3UDByMThtWF9CMWtSS3AwNmFTR081ZkRiRnp3d2pIREVQVnFGc3E3WW9xcTQtYjcyN1BCZFlwNklqUld6dGN3Rk1DN1g0a0g2NUpaWU41UGFOdVctUUVMOWtNcHEwUW5HZHoteWJIYW9INU8xeElKZkp1MHlaUmRWWWFfbGJYQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVVpEQzdQdUY5cXkwU3ZVSG5QY1RzUU1BVjYySUMwdFYtZ2phNS12Rm1NZUo2VUxsUEpNYzRjdWVTSzFPTkxHX1I4dDNYMWp2WUo4R25kVzZXRjRkc09DNnJSanhjUy1fcVctWTRPVk9kVG5nSG1nQUstajliTW45MndfcEc4bHY4MWxF0gGLAUFVX3lxTE1VWkRDN1B1RjlxeTBTdlVIblBjVHNRTUFWNjJJQzB0Vi1namE1LXZGbU1lSjZVTGxQSk1jNGN1ZVNLMU9OTEdfUjh0M1gxanZZSjhHbmRXNldGNGRzT0M2clJqeGNTLV9xVy1ZNE9WT2RUbmdIbWdBSy1qOWJNbjkyd19wRzhsdjgxbEU?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New Xilio hire gets stock options for 1,982 shares at $8.32", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYjNlT0VCWXllXzhkREZVNXJzb1VKMnNlRFgtc254LUI3OGljVm4xZHlQOVBob3ZPeThIVkowR1hMZ0szZ0tqQU9Xd1doc0VnZHQwcTRvQnc3UWlQY0tDYVBrZzh6bnlSSWN0azU3ZDZhS0xFSGpHakVFVXNuUzAyOVI4Z2h1cmJFWGQ1SHZzWnk0Nnk4Vkg1OTdLbzlZemJEXzFpRXNocmpDeU5wSXRuR1VnTGxyd0hfLUVGandB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkpPQW5RMkxPT1BLV1RqczZtbjNXQmducGRXTVdVMjUzODFCbkJFc2stbVJ4ZmRiemZwQ2Q2UjE3U1BaaDJJMDNzbGtheDdIRy1yTHMxQVo1d1ZSZTEzbmhUT3FOVjhWbXdhZ25mVkxfOHEyQjhvX0QwWGJCcjhiXzVFNzh2VUFPbG5UUmstLWREUldBU0hJT0wwM20xTVdWOUE?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xilio Therapeutics Announces 1-for-14 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUi1NTlR2WW9nWS1ZYzJOVldvQjlaZ3RjS1ppRUQ5VjVvTTVuem4wbmRuVmRHMDVrbzBFVVlpbFBZRHY3Tm5wdE9YU2daMTRGakhkN0c5RldBSFZHYURTdUxWRE9zblVjajhuVnBGNFo2SFdxREtVWGJMTFJudVZFUmVjdWdmLXMtN19kUHBIV2VCcE9qX1BXc1B3YWJFQ1JSakZvcHhYLXFKZXZrd3o5RkJJZFd4ZVlicUk1Vm5pd2xJa0xkN2hMSA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOemRDQjBGcE5jaVhLdV8zVmlDeWs3SU9NVU9EZC1zYjNfT3dxUFZqNF81X1BibWVySm4tQ21JalFHTTVvUjVLYlI4bDVWLWhLY3hxemJaYXk5bFZRS0JvSVdaUFRJYWlSSEg2aHI0N3lJWWVNYWtfMnJCQ2xKNzZHd0pQbDhWd2lVQ09mYnZzYXl4OEt4MGJfWU1GZw?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFBsUk1Tc2tadEJZYkhZc0cyUGM5cEVXQ1FJUjRvUlBfSEIxWUZ6T09Xb3VJd3E3N1JMTUR6NFpKNHdOVEJTdURMVHBSM3V6TEJSN1E?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:38:01+00:00", "published_display": "24 Apr 2025 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Stock Forecast and Price Target 2026 $XLO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9zT3FZSVdTQS1iTGNXVUdHRzk2M1lxTFJHWjlTN0hEanNJUHN6LVpfcU9zMldyc1p5WjJlYnU5Qkl4NWc2aEdmM29IZEJsOTZsUG1MMXZqcGFqVjhJdjVPM28yX00?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:17:17+00:00", "published_display": "11 May 2024 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Xilio Therapeutics, Inc. announced the grant of non-qualified stock options to purchase 107,060 shares of its common stock to three new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan, with an exercise price of $9.22 per share, matching ", "url": "https://finance.yahoo.com/healthcare/articles/xilio-therapeutics-announces-inducement-grants-203000264.html", "source_name": "Market source", "published_at": "2026-07-09T12:42:25", "published_display": "09 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xilio Therapeutics, Inc. \u2013 NASDAQ:XLO", "summary": "This article focuses on the enterprise value to EBIT forward for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content primarily consists of navigational and bra", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:11:18", "published_display": "07 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio lures three new employees with 107,060 stock options", "summary": "Xilio Therapeutics (Nasdaq: XLO) has granted non-qualified stock options for 107,060 shares to three new employees, effective July 1, 2026. These options, with an exercise price of $9.22 per share and a ten-year term, serve as an inducement under Nasdaq Listing Rule 5635(c)(4). T", "url": "https://www.stocktitan.net/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-w0d8bd87n4rj.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:09:27", "published_display": "06 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his over two decades of legal and executive experience in the biopharmaceutical industry. Harshbarger previously served as chief legal officer at Astria Therapeutics and held leadership ro", "url": "https://za.investing.com/news/stock-market-news/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-93CH-4347544", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T08:09:48", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xilio Therapeutics, Inc. \u2013 NASDAQ:XLO", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company over a defined period. The content primarily lists nav", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:19", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index", "summary": "Xilio Therapeutics, Inc. (NasdaqCM:XLO) has been added to the Russell Microcap Value Benchmark Index, as announced on June 29, 2026. This move highlights the company's position within the microcap market and its valuation metrics. Xilio Therapeutics operates as a clinical-stage b", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-nasdaqcm-xlo-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:11:24", "published_display": "29 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. \u2013 BOATS:XLO", "summary": "This article provides financial information for Xilio Therapeutics, Inc. (XLO), specifically its enterprise value to EBITDA forward metric. The content highlights a specific financial indicator for the company, accessible through the Blue Ocean Alternative Trade System (BOATS) vi", "url": "https://www.tradingview.com/symbols/BOATS-XLO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:11:24", "published_display": "29 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer", "summary": "Xilio Therapeutics, Inc. has announced the appointment of Ben Harshbarger as its new Chief Legal Officer. Harshbarger brings over two decades of legal and executive leadership experience in the biopharmaceutical industry, having previously served as Chief Legal Officer at Astria ", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-announces-appointment-of-ben-harshbarger-as-chief-legal-officer-ce7f5fded08af324", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:11:24", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his extensive legal and strategic experience in the biotechnology sector. Harshbarger's role will be crucial in advancing Xilio's pipeline of immuno-oncology therapies, including the bispe", "url": "https://www.quiverquant.com/news/Xilio+Therapeutics+Appoints+Ben+Harshbarger+as+Chief+Legal+Officer", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T11:41:00", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief", "summary": "Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, bringing over 20 years of biopharmaceutical legal and executive experience to the company. Harshbarger previously served at Astria Therapeutics, Novelion Therapeutics, Aegerion, Cubist, ViaCell, and ", "url": "https://www.stocktitan.net/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-jsgkw9sa1yho.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:11:24", "published_display": "29 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xilio Therapeutics, Inc. \u2013 BOATS:XLO", "summary": "The article focuses on the enterprise value to revenue forward metric for Xilio Therapeutics, Inc. (XLO). It appears to be a financial data presentation or analysis page from TradingView, specifically looking at Xilio Therapeutics' financials within the pharmaceutical sector. The", "url": "https://www.tradingview.com/symbols/BOATS-XLO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:41:09", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index", "summary": "Xilio Therapeutics, Inc. (NasdaqCM: XLO) has been added to the Russell Microcap Index. The clinical-stage biotechnology company focuses on developing masked immuno-oncology therapies to treat cancer with reduced systemic side effects. Xilio Therapeutics also reported its first-qu", "url": "https://www.marketscreener.com/news/xilio-therapeutics-inc-nasdaqcm-xlo-added-to-russell-microcap-index-ce7f5fdedd88f520", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T01:50:00", "published_display": "29 Jun 2026 01:50", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XLO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Xilio Therapeutics, Inc. (XLO) stock, based on analyst opinions. It covers current stock performance, historical highs and lows, volatility metrics, market capitalization, and financial data including earnings, revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:26", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO)", "summary": "This article provides an overview of Xilio Therapeutics Inc. (NASDAQ: XLO), including its current stock price, historical performance, analyst forecasts, and financial data. It covers earnings per share, revenue, market capitalization, and volatility, along with information on fu", "url": "https://www.tradingview.com/symbols/NASDAQ-XLO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:56", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Edges Higher in Low-Volume Trading, Testing Key Resistance - OBV Trend Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOXZFZi1ONWpWQl9EREwySVdPQjdpSWR5djRMclFPVENndzR2SG9XX0FGRHFxOFphZnNXQW9pZ2VRV1dCZzQ2clpENTRBLU9YLXY5Y29UaHdTRG5xN3JDS3MwZ19kdjdtV2hmYzVIc3haM2paN25wNFNuMU5PcjRjdU94WkY5TmJKbnhNRkFTUUh3aUZGUmk2b19MYnYycmduTFlQaFJtbW9ReDBFdGxXZmxWLVU4aU5iWEJN?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividends and stock splits for Xilio Therapeutics Inc (XLO). It indicates that the company has not distributed any dividends in the past five years. However, it notes a 14-to-1 merger-related stock split effective March 12, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xlo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xilio Therapeutics Inc (XLO), highlighting its perfect earnings forecast score of 10.00 and a 'Strong Buy' analyst rating from one analyst. It details the average price target of $2.00, along with expected revenue and EPS for upcomin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xlo/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T01:40:39", "published_display": "17 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes", "summary": "Xilio Therapeutics has modified its board structure following its annual meeting by rebalancing its classified board and reappointing Daniel Curran as a Class III director. Shareholders also elected four Class II directors, ratified Ernst & Young LLP as the auditor, and approved ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XLO-Q/pressreleases/2458209/xilio-therapeutics-adjusts-board-structure-following-shareholder-votes/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T02:39:53", "published_display": "14 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio (XLO) director receives grant of 5,000 stock options at $7.99", "summary": "Xilio Therapeutics director Shannon James Samuel was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company\u2019s next annual stockholder meeting, contingent on his continued service. Following", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-cca81b1d18ac.html", "source_name": "Stock Titan", "published_at": "2026-06-13T13:09:59", "published_display": "13 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99", "summary": "Xilio Therapeutics director Daniel J. Curran was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company's next annual meeting, contingent on his continued service. This transaction is a com", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-9a32f35e3b52.html", "source_name": "Stock Titan", "published_at": "2026-06-13T12:10:28", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daniel Curran reappointed to Class III director at Xilio", "summary": "Xilio Therapeutics has reappointed Daniel Curran as a Class III director after he resigned as a Class II director to rebalance the board. This change, effective June 10, 2026, aims to achieve an equal balance of director membership across the three classes of the Board. The infor", "url": "https://www.tradingview.com/news/tradingview:69c8358eb5b5c:0-daniel-curran-reappointed-to-class-iii-director-at-xilio/", "source_name": "TradingView", "published_at": "2026-06-12T20:39:41", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO)", "summary": "Xilio Therapeutics (NASDAQ: XLO) reported governance and compensation updates from its 2026 annual stockholder meeting. The company rebalanced its staggered board, moving Daniel Curran, M.D. from a Class II to a Class III director position without changing his compensation. Stock", "url": "https://www.stocktitan.net/sec-filings/XLO/8-k-xilio-therapeutics-inc-reports-material-event-82f08ec0c610.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:42", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options", "summary": "Xilio Therapeutics director Xu Yuan was granted 5,000 stock options as equity compensation, with an exercise price of $7.99 per share and an expiration date of June 10, 2036. The options, granted on June 11, 2026, will fully vest on the earlier of June 11, 2027, or the company's ", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-434d6ace3642.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:41", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99", "summary": "Xilio Therapeutics director Aoife Brennan was granted options for 5,000 shares of common stock at an exercise price of $7.99 per share. The options expire on June 10, 2036, and will vest 100% on the earlier of June 11, 2027, or the next annual stockholder meeting, contingent on h", "url": "https://www.stocktitan.net/sec-filings/XLO/form-4-xilio-therapeutics-inc-insider-trading-activity-9a2083d16127.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:41", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Shows Resilience with 1.91% Gain, Approaching Key Resistance - Dark Pool Prints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPSGRPazFBRVppVUZ5Z3ltdDk4VlBwWGxwNWxiRFN3T21YN3hyelZBZG9lcklndTlYZUFfWGJtQnhvTFM0VzBUMm90LV85ZmRBSF91WVJidVN0ODlsdGhVeFpFZWY1cU9uX2dPWE1ZWmUxM0ppNlE2aTlhX0JJc21RZlNReVFSWmc1YkhESDI5VnVuT2dDR0xaNUM1bU12ajhteWRTanFwUDJWUE1pNl9sSmZjV0Q1enVIenMtc1dfcHJqQnM?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSThhdGU0UG1nSV9zYVZ5ZFlwdnR3UFZjSmVfVm44TFRrZHhPWndRdF9kUmpTbUVOVXdHLVFrb3l4cGZXSFB3TG9xeWpEQWhtUDNRalo2Z3phYkYwbjBxMDg0dlhSUUxhLVVvOTZYTDVuYTlONmRldWFYelFQMkR5R0NiU3gtajd2RWxoc2tzWmpWVWdqU1dtUjcwLWVVMXNEMEp2LUJ3?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxNdVduVnhqV2JRbVpJX0tzbGNlb2ROM2JUc01FWllsMW5TT3I2S0lvemJ2SWNkaGVLV1hlTHlESWFQRE9vckZ1UUFYREo0TnU2NUtaVE04cWs2eVhkWFY2bDdwcnR1MHJtME1xakh6T3hMUlhKVXlHbEJNeGNOcGlhNFBzTVBYSWU4OFM3UDByMThtWF9CMWtSS3AwNmFTR081ZkRiRnp3d2pIREVQVnFGc3E3WW9xcTQtYjcyN1BCZFlwNklqUld6dGN3Rk1DN1g0a0g2NUpaWU41UGFOdVctUUVMOWtNcHEwUW5HZHoteWJIYW9INU8xeElKZkp1MHlaUmRWWWFfbGJYQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVVpEQzdQdUY5cXkwU3ZVSG5QY1RzUU1BVjYySUMwdFYtZ2phNS12Rm1NZUo2VUxsUEpNYzRjdWVTSzFPTkxHX1I4dDNYMWp2WUo4R25kVzZXRjRkc09DNnJSanhjUy1fcVctWTRPVk9kVG5nSG1nQUstajliTW45MndfcEc4bHY4MWxF0gGLAUFVX3lxTE1VWkRDN1B1RjlxeTBTdlVIblBjVHNRTUFWNjJJQzB0Vi1namE1LXZGbU1lSjZVTGxQSk1jNGN1ZVNLMU9OTEdfUjh0M1gxanZZSjhHbmRXNldGNGRzT0M2clJqeGNTLV9xVy1ZNE9WT2RUbmdIbWdBSy1qOWJNbjkyd19wRzhsdjgxbEU?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Xilio hire gets stock options for 1,982 shares at $8.32", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYjNlT0VCWXllXzhkREZVNXJzb1VKMnNlRFgtc254LUI3OGljVm4xZHlQOVBob3ZPeThIVkowR1hMZ0szZ0tqQU9Xd1doc0VnZHQwcTRvQnc3UWlQY0tDYVBrZzh6bnlSSWN0azU3ZDZhS0xFSGpHakVFVXNuUzAyOVI4Z2h1cmJFWGQ1SHZzWnk0Nnk4Vkg1OTdLbzlZemJEXzFpRXNocmpDeU5wSXRuR1VnTGxyd0hfLUVGandB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkpPQW5RMkxPT1BLV1RqczZtbjNXQmducGRXTVdVMjUzODFCbkJFc2stbVJ4ZmRiemZwQ2Q2UjE3U1BaaDJJMDNzbGtheDdIRy1yTHMxQVo1d1ZSZTEzbmhUT3FOVjhWbXdhZ25mVkxfOHEyQjhvX0QwWGJCcjhiXzVFNzh2VUFPbG5UUmstLWREUldBU0hJT0wwM20xTVdWOUE?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Announces 1-for-14 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUi1NTlR2WW9nWS1ZYzJOVldvQjlaZ3RjS1ppRUQ5VjVvTTVuem4wbmRuVmRHMDVrbzBFVVlpbFBZRHY3Tm5wdE9YU2daMTRGakhkN0c5RldBSFZHYURTdUxWRE9zblVjajhuVnBGNFo2SFdxREtVWGJMTFJudVZFUmVjdWdmLXMtN19kUHBIV2VCcE9qX1BXc1B3YWJFQ1JSakZvcHhYLXFKZXZrd3o5RkJJZFd4ZVlicUk1Vm5pd2xJa0xkN2hMSA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOemRDQjBGcE5jaVhLdV8zVmlDeWs3SU9NVU9EZC1zYjNfT3dxUFZqNF81X1BibWVySm4tQ21JalFHTTVvUjVLYlI4bDVWLWhLY3hxemJaYXk5bFZRS0JvSVdaUFRJYWlSSEg2aHI0N3lJWWVNYWtfMnJCQ2xKNzZHd0pQbDhWd2lVQ09mYnZzYXl4OEt4MGJfWU1GZw?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFBsUk1Tc2tadEJZYkhZc0cyUGM5cEVXQ1FJUjRvUlBfSEIxWUZ6T09Xb3VJd3E3N1JMTUR6NFpKNHdOVEJTdURMVHBSM3V6TEJSN1E?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:38:01+00:00", "published_display": "24 Apr 2025 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xilio Therapeutics (XLO) Stock Forecast and Price Target 2026 $XLO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9zT3FZSVdTQS1iTGNXVUdHRzk2M1lxTFJHWjlTN0hEanNJUHN6LVpfcU9zMldyc1p5WjJlYnU5Qkl4NWc2aEdmM29IZEJsOTZsUG1MMXZqcGFqVjhJdjVPM28yX00?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:17:17+00:00", "published_display": "11 May 2024 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 79, "total_relevant": 43, "sentiment_summary": {"positive": 13, "negative": 1, "neutral": 29, "score": 56, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 9.1, "latest_week": "2026-07-10", "one_week_move": -0.5, "four_week_move": 9.5, "twelve_week_move": 6.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.2855, "market_dynamics_buy_signal": false, "relative_strength": -15.93699, "fair_value_gap": -33.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.7747, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.5% over one week, +9.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "www.marketscreener.com", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 34}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "34", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.5% over one week, +9.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}], "updated_at": "2026-07-17T22:21:33.062208+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}